BLFS Biolife Solutions Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLFS

Price (delayed)

$18.03

Market cap

$816.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.52

Enterprise value

$824.01M

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage ...

Highlights
The EPS has surged by 54% year-on-year and by 36% since the previous quarter
BLFS's net income has surged by 52% year-on-year and by 35% since the previous quarter
BLFS's quick ratio is down by 23% year-on-year but it is up by 8% since the previous quarter
The company's gross profit fell by 13% YoY and by 9% QoQ
The company's revenue fell by 11% YoY and by 7% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.biolifesolutions.com
Peers: CE ENTA

Key stats

What are the main financial stats of BLFS
Market
Shares outstanding
45.3M
Market cap
$816.76M
Enterprise value
$824.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
5.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.75
Earnings
Revenue
$143.27M
EBIT
-$64.45M
EBITDA
-$51.75M
Free cash flow
-$23.74M
Per share
EPS
-$1.52
Free cash flow per share
-$0.54
Book value per share
$7.67
Revenue per share
$3.28
TBVPS
$3.82
Balance sheet
Total assets
$412.71M
Total liabilities
$75.05M
Debt
$42.69M
Equity
$337.66M
Working capital
$78.43M
Liquidity
Debt to equity
0.13
Current ratio
2.86
Quick ratio
1.67
Net debt/EBITDA
-0.14
Margins
EBITDA margin
-36.1%
Gross margin
32.6%
Net margin
-46.4%
Operating margin
-51%
Efficiency
Return on assets
-15.6%
Return on equity
-19.3%
Return on invested capital
-42.3%
Return on capital employed
-17.4%
Return on sales
-45%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLFS stock price

How has the Biolife Solutions stock price performed over time
Intraday
-0.72%
1 week
2.85%
1 month
4.1%
1 year
1.86%
YTD
10.95%
QTD
-2.8%

Financial performance

How have Biolife Solutions's revenue and profit performed over time
Revenue
$143.27M
Gross profit
$46.75M
Operating income
-$73.02M
Net income
-$66.43M
Gross margin
32.6%
Net margin
-46.4%
BLFS's net income has surged by 52% year-on-year and by 35% since the previous quarter
BLFS's operating income has soared by 51% YoY and by 34% QoQ
The net margin has grown by 46% year-on-year and by 30% since the previous quarter
The operating margin has increased by 45% YoY and by 28% from the previous quarter

Growth

What is Biolife Solutions's growth rate over time

Valuation

What is Biolife Solutions stock price valuation
BLFS P/E details
P/E
N/A
P/B
2.35
P/S
5.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.75
The EPS has surged by 54% year-on-year and by 36% since the previous quarter
BLFS's price to book (P/B) is 36% lower than its 5-year quarterly average of 3.7 but 2.2% higher than its last 4 quarters average of 2.3
The equity has contracted by 7% YoY
The P/S is 52% lower than the 5-year quarterly average of 11.4 but 8% higher than the last 4 quarters average of 5.1
The company's revenue fell by 11% YoY and by 7% QoQ

Efficiency

How efficient is Biolife Solutions business performance
The ROIC has soared by 57% YoY and by 31% from the previous quarter
The return on sales has grown by 49% year-on-year and by 31% since the previous quarter
Biolife Solutions's return on assets has increased by 45% YoY and by 34% QoQ
The ROE has grown by 43% YoY and by 34% from the previous quarter

Dividends

What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLFS.

Financial health

How did Biolife Solutions financials performed over time
BLFS's quick ratio is down by 23% year-on-year but it is up by 8% since the previous quarter
The total liabilities has decreased by 13% YoY and by 5% from the previous quarter
The debt is 87% smaller than the equity
Biolife Solutions's debt to equity has increased by 8% YoY
The equity has contracted by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.